Maltodextrin/ascorbic acid stimulates wound closure by increasing collagen turnover and TGF-ß1 expression in vitro and changing the stage of inflammation from chronic to acute in vivo.

It has been reported that carbohydrates confer physicochemical properties to the wound environment that improves tissue repair. We evaluated in vitro and in vivo wound healing during maltodextrin/ascorbic acid treatment. In a fibroblast monolayer scratch assay, we demonstrated that maltodextrin/ascorbic acid stimulated monolayer repair by increasing collagen turnover coordinately with TGF-ß1 expression (rising TGF-ß1 and MMP-1 expression, as well as gelatinase activity, while TIMP-1 was diminished), similar to in vivo trends. On the other hand, we observed that venous leg ulcers treated with maltodextrin/ascorbic acid diminished microorganism population and improved wound repair during a 12 week period. When maltodextrin/ascorbic acid treatment was compared with zinc oxide, almost four fold wound closure was evidenced. Tissue architecture and granulation were improved after the carbohydrate treatment also, since patients that received maltodextrin/ascorbic acid showed lower type I collagen fiber levels and increased extracellular alkaline phosphatase activity and blood vessels than those treated with zinc oxide. We hypothesize that maltodextrin/ascorbic acid treatment stimulated tissue repair of chronic wounds by changing the stage of inflammation and modifying collagen turnover directly through fibroblast response.

[Bone loss treatment, pseudoarthrosis, arthrodesis and benign tumors using xenoimplant: clinical study].

BACKGROUND: Bone loss as a result of arthrodesis, pseudarthrosis, benign tumors and bone defects was treated using a xenoimplant (Nukbone). METHODS: The effectiveness of the material was evaluated through a longitudinal and observational study at the Hospital Regional "General Ignacio Zaragoza" (HRGIZ) ISSSTE. The Mexican xenoimplant is a patent of the National Autonomous University of Mexico (UNAM). RESULTS: Fifty two patients were considered regardless of age or gender. Of these patients, 28 were male and 24 female. Average age of the patients was 47.7 years (9-84 years). Twenty eight patients had arthrodesis, 16 were treated with pseudarthrosis, three patients had benign tumors and five patients presented bone defects, which were implanted with Nukbone at the site and was the correct treatment for the problem. The xenoimplant is fully integrated during a period of 3-18 months, depending on the size of the pathology and the region where it was placed. Fracture healing was evaluated radiographically according to the classification of Montoya. No patient had clinical signs of rejection. CONCLUSIONS: In Mexico, bony xenoimplants (osseous) have been used, all of foreign origin due to the high degree of technological dependence in this country. In this study we describe the use, for the first time, of a Mexican xenoimplant with a patent from the Universidad Nacional Autónoma de México (UNAM). The Mexican xenoimplant is biocompatible and can be adapted to treat pathologies where bony (osseous) material is needed.

Tratamiento de pérdidas óseas, pseudoartrosis, artrodesis y tumores óseos benignos con un xenoimplante mexicano (estudio clínico) / Bone loss treatment, pseudoarthrosis, arthrodesis and benign tumors using xenoimplant: clinical study

Objetivo: Se trataron pérdidas óseas, artrodesis, pseudoartrosis, tumores benignos y defectos óseos con un xenoimplante. Material y métodos: Se evaluó la eficacia del material mediante un estudio observacional y longitudinal en el Hospital Regional “General Ignacio Zaragoza” del ISSSTE. Resultados: Fueron considerados 52 pacientes, 28 masculinos y 24 femeninos, de los cuales a 28 se les practicó artrodesis, 16 fueron tratados por pseudoartrosis, tres presentaron tumores óseos benignos y cinco defectos óseos, a los cuales se les colocó el xenoimplante en el sitio y forma adecuada según el problema por tratar. El promedio de edad de los pacientes fue de 47.7 años, con un rango de nueve a 84 años. Se presentó consolidación ósea entre los tres y ocho meses después de la cirugía; el xenoimplante se integró totalmente en un periodo de tres a 18 meses dependiendo del tamaño de la patología y la región donde fue colocado. La consolidación ósea fue valorada radiográficamente de acuerdo con la clasificación de Montoya. Ningún paciente presentó signos clínicos de rechazo. Conclusiones: En México se han empleado xenoimplantes óseos de origen extranjero debido a la gran dependencia tecnológica del país. Por primera vez se utiliza un xenoimplante producido en el país y cuya patente es de la Universidad Nacional Autónoma de México. El xenoimplante Nukbone® fue biocompatible y resultó adecuado para tratar patologías donde se requiere aporte óseo.

BACKGROUND: Bone loss as a result of arthrodesis, pseudarthrosis, benign tumors and bone defects was treated using a xenoimplant (Nukbone). METHODS: The effectiveness of the material was evaluated through a longitudinal and observational study at the Hospital Regional "General Ignacio Zaragoza" (HRGIZ) ISSSTE. The Mexican xenoimplant is a patent of the National Autonomous University of Mexico (UNAM). RESULTS: Fifty two patients were considered regardless of age or gender. Of these patients, 28 were male and 24 female. Average age of the patients was 47.7 years (9-84 years). Twenty eight patients had arthrodesis, 16 were treated with pseudarthrosis, three patients had benign tumors and five patients presented bone defects, which were implanted with Nukbone at the site and was the correct treatment for the problem. The xenoimplant is fully integrated during a period of 3-18 months, depending on the size of the pathology and the region where it was placed. Fracture healing was evaluated radiographically according to the classification of Montoya. No patient had clinical signs of rejection. CONCLUSIONS: In Mexico, bony xenoimplants (osseous) have been used, all of foreign origin due to the high degree of technological dependence in this country. In this study we describe the use, for the first time, of a Mexican xenoimplant with a patent from the Universidad Nacional Autónoma de México (UNAM). The Mexican xenoimplant is biocompatible and can be adapted to treat pathologies where bony (osseous) material is needed.